The Genetic Correction of Aging: How DNA Editing Extended Mouse Lifespan by 140%

How can aging be slowed? One of the most challenging approaches is to treat people who already carry aging in their genes. Children with progeria (Hutchinson-Gilford Progeria Syndrome) carry a single mutation in the LMNA gene that causes them to age 5-10 times faster than normal. They lose hair by age 2, develop atherosclerosis by age 5, and typically die from a heart attack before age 13. For decades, medicine offered nothing. Now, a team from the NIH and the Broad Institute has shown that DNA editing therapy can correct the mutation and extend lifespan in mice by 140%. The treatment is now on its way to clinical trials in children. And it has major implications for everyone.

The Problem: One Error in One Gene

Progeria is caused by a point mutation - a single altered bit in the DNA. The LMNA gene encodes a protein called lamin A, which forms the protein layer inside the nucleus of every cell in the body. Under normal conditions, lamin A stabilizes the nucleus and protects genetic information. In the mutated state, a defective version called progerin is produced that does not clear properly. It accumulates in the nucleus, causes deformation, and ultimately cells die prematurely.

The surprise: even healthy cells, in adults without progeria, produce tiny amounts of progerin. It accumulates in all of us with age. This may be one of the causes of "normal" aging. The progeria mutation only causes progerin to be produced in larger quantities.

The Solution: Repairing the Gene Itself

A team led by Prof. David Liu from the Broad Institute, with collaborators from the NIH (NHGRI) and Vanderbilt University Medical Center, developed a new approach. Instead of cutting the DNA (as in classic CRISPR), it uses base editing - correcting a single genetic letter. Like fixing a typo in a word on a computer, without deleting the entire word.

The method:

1. Load the base editor onto an AAV virus (a harmless virus used as a delivery vehicle)
2. Inject the virus into the patient
3. The virus reaches all cells in the body
4. In each cell, the base editor locates the damaged DNA and corrects the specific letter
5. From that moment, the cell produces normal lamin A instead of progerin

The Results in Mice: Dramatic

The team published the original experiment in Nature in 2021. They worked with mice carrying the same mutation as children with progeria. Without treatment, the median lifespan of these mice is about 215 days (compared to 800-1000 days for a normal mouse).

After a single treatment with the base editor:

• Median lifespan increased from 215 to 510 days - an extension of about 140%, roughly 2.5 times
• Mutation correction in the living body ranged from about 10% to 60% of cells, depending on the organ; in cultured cells from progeria patients, correction reached about 90% - enough for a dramatic effect
• Heart function returned to nearly normal
• Arterial pathology was halted and aortic structure was preserved
• Nuclear structure in cells returned to normal
• No discernible side effects

"Aortic samples were almost indistinguishable from samples of a normal mouse, and that was amazing" (Prof. David Liu).

The Journey to the Clinic

After the successful 2021 experiment, time was needed for development toward humans:

1. 2022-2023: Experiments in monkeys to test safety and efficacy
2. 2024-2025: Production of the drug version (SamPro-2) to pharmaceutical standards
3. March 2026: Partnership with Forge for commercial manufacturing
4. 2027: Expected FDA approval for Phase 1 clinical trial
5. 2028: Expected treatment of the first human child with progeria

The Progeria Research Foundation (PRF) is leading the process, along with academic teams.

Additional Therapies in Development

In addition to base editing, other approaches for treating progeria are being developed:

• BPIFB4 gene: A gene identified in super-centenarians (people over 100). Researchers from the University of Bristol and IRCCS MultiMedica showed that injecting LAV-BPIFB4 into progeria mice improved diastolic heart function and reduced cellular senescence and cardiac fibrosis.
• Lonafarnib: The first drug approved by the FDA in 2020 for progeria. It works by reducing progerin production. In long-term follow-up (about 11 years), it was associated with an average lifespan extension of about 2.5 years. It's not a revolutionary drug, but it's a start.
• Antisense oligonucleotides: Another approach that silences the defective RNA

Why This Matters for Everyone

The magic of progeria is that it is an accelerated version of normal aging. Any mechanism that works in progeria has a good chance of working in normal aging as well:

• Progerin accumulates in all of us with age, just a little. A base editor can correct this.
• Our aged cells resemble progeria cells in their nuclear structure.
• Treatments that work in progeria will later be tested in the general population.

Liu's team is already working on expanding the treatment. If base editing is safe in progeria children, it could be offered to older people with a genetic predisposition to accelerated aging. The vision for 10-15 years from now: genetic therapy that corrects aging at the cellular level.

The Challenges

Even if the clinic succeeds, there are limitations:

• Cost: Gene therapies cost 2-4 million dollars per patient. This needs to come down.
• Availability: Progeria affects 1 in 4 million. The small scale makes investment difficult.
• Expansion to the general population: Moving from progeria (one mutation in all patients) to normal aging (thousands of different mutations in each person) is a big leap.
• Long-term safety: DNA editing in children will cause changes we haven't seen before. The first patients must be followed for decades.

What You Can Do Now

Even without this treatment, there are things you can do to reduce progerin in the body:

• Avoid excessive UV radiation: Sun damages LMNA
• Diet low in processed foods: Metabolic load increases progerin production
• Regular physical activity: Accelerates cellular cleanup that removes accumulated progerin
• Mild caloric restriction: Activates autophagy that removes damaged proteins, including progerin

The Bottom Line

Progeria was for decades a cruel secret of medicine: children aging fast with no one able to help. Now the story is changing. Within ten years, there may be a cure for this disease. And more than that, it will open the door to treatments for aging in all of us. What was once loneliness becomes hope.